Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on June 6 and set a price target of $49.00. The analyst based the rating on the company’s promising developments and data, citing the preclinical data for BP1.15205.

Presented at the SLEEP 2025 conference, the data highlights significant clinical activity in an orexin/ataxin-3 mouse model, with no noted safety concerns and a wide therapeutic index. This is a positive factor for the drug’s efficacy, as it points towards the potential for nearly complete wakefulness at low doses.

Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now?

A close-up of a pharmaceutical drug bottle, showcasing the potential of the company’s innovative therapies.

The analyst further supported the optimistic rating for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) with comparative data from other compounds, such as ORX750 and TAK-861, which demonstrated promising results with considerable wakefulness and a reduction in cataplexy episodes. All these factors contribute to a bullish outlook for the company’s pipeline for addressing unmet needs in sleep disorders.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.

While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.